As the need for access to guideline-concordant biomarker testing for underserved populations continues to grow, hear what care teams need to know about coverage for Medicaid beneficiaries and the legislative outlook for 2024. In this episode, CANCER BUZZ speaks with Hilary Gee Goeckner, MSW, director of State and Local Campaigns for the American Cancer Society Cancer Action Network (ASC CAN), who shares policy perspectives and the latest on state legislation to expand coverage for biomarker testing for Medicaid beneficiaries.
“There are a lot of challenges around implementation—getting the legislation passed is just the first step…It is also important for providers to be aware of the new rules that affect many plans and their states so they are able to order testing that may not have been covered or rejected previously.” –Hilary Gee Goeckner, MSW
Hilary Gee Goeckner, MSW
Director, State and Local Campaigns, Access to Care
American Cancer Society Cancer Action Network
Washington, D.C.
This episode was developed in connection with the ACCC education program Improving Access to Biomarker Testing in Medicaid Populations and is made possible with support by Foundation Medicine and Exact Sciences.
Resources:
The Cost of Biomarker Testing: Moving from Support-Based to Sustainable Solutions
Comprehensive Cancer Care: The Role of Biomarker Testing
Biomarker Testing for Medicaid Beneficiaries (Podcast)
Access to Biomarker Testing - American Cancer Society Cancer Action Network
The Road to Comprehensive Biomarker Testing for All – ACCC Buzz Blog
Improving Access to Biomarker Testing in Medicaid Populations
Precision Medicine in Rural and Underserved Areas – ACCC Buzz Blog
Patient Perceptions of Biomarker Testing – Oncology Issues
Cancer Diagnostics - Biomarkers
Eliminating Precision Medicine Disparities
Biomarker Testing for NTRK Gene Fusions
Cancer Care Team Mental Health: Normalizing Helpers Seeking Help
Key Highlights from an ACCC Survey on Remote Patient Monitoring
Alleviating the Psycho-social Burden of MPNs
Myelofibrosis: Advances in Treatment and Therapy
ACCC’s 2023 Advocacy Agenda and Priorities
Symptoms Scoring and Risk Stratification for Myelofibrosis
Utilizing Subcutaneous and IV Treatment for Improved Outcomes with Multiple Myeloma Patients
A Better Patient Experience in the Management of Incidental Lung Nodules
In the Know: New Treatment Guidelines for Myeloproliferative Neoplasms
Mitigating the Financial Burden of Cancer Diagnostics
Getting the Green Light for Precision Medicine Stewards
The Impact of Integrated Care on Myeloproliferative Neoplasms (MPNs)
Treatment Options for Patients with Multiple Myeloma Who Are Ineligible for Transplant
Best Practices in Caring for Patients with CLL in a Post-COVID Era
Addressing Regional Challenges to Equitable Care for Patients with CLL
Robots, Biologics, and Advocates: Lessons from the Pharmacy
Precision Medicine: Stories from the CRISPR Revolution
The Urgency of MPN Treatment – Why Timing Matters
The Role of Population Health Navigators
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Museum of the Missing
Strange by Nature Podcast
Sasquatch Chronicles
Hidden Brain